Ceesay Abraham 4

What Happened

• Ceesay Abraham, CEO of Rapport Therapeutics, sold a total of 10,916 shares in open-market transactions on January 20, 2026. The sales were reported as two transactions: 5,833 shares at a weighted average price of $26.12 (≈ $152,333) and 5,083 shares at a weighted average price of $26.11 (≈ $132,737), for a combined proceeds of about $285,070. These were sales (not purchases), so they represent disposition of stock rather than a bullish buy.

Key Details

• Transaction date: January 20, 2026
• Report filed: January 22, 2026 (no late filing indicated in the provided record)
• Prices: weighted average prices reported ($26.11–$26.12); shares were sold in multiple transactions at prices ranging from $25.83 to $26.70
• Shares sold: 5,833 and 5,083 (total 10,916)
• Total proceeds: approx. $285,070
• Shares owned after transaction: Not specified in the provided summary (see the full Form 4 for post-transaction holdings)
• Notable footnotes:
  • Sales were effected pursuant to a Rule 10b5-1 trading plan adopted Dec 12, 2024 (pre-scheduled trades) — F1
  • Weighted-average pricing noted; Reporting Person will provide per-price breakdown upon request — F2/F3
  • Certain shares are held by family irrevocable trusts; the Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest — F4/F5

Context

• Trades executed under a 10b5-1 plan are prearranged and commonly used by insiders to sell shares on a scheduled basis; they do not necessarily signal a change in the insider’s view of the company.
• The filing reports outright sales (transaction code S). For retail investors, purchases typically carry more direct informational weight; sales can be routine or for diversification/liquidity reasons.